Perrigo | PRGO - Cash And Equivalent



Perrigo reported $454.2M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
Abbott USD 6.95B 419M Jun/2025
Bayer EUR 4.56B 542M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Corcept Therapeutics USD 102.74M 12.93M Jun/2025
Dr.Reddys Laboratories INR 9B 5.65B Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
J&J USD 38.47B 32.35B Mar/2025
Merck USD 8.01B 622M Jun/2025
Nestle CHF 4.65B 904M Jun/2025
Pacira USD 300.48M 16.87M Jun/2025
Perrigo USD 454.2M 44.3M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Prestige Brands USD 139.5M 41.62M Jun/2025
Reckitt Benckiser GBP 880M 106M Dec/2024
Sanofi 15.36B 7.37B Jun/2025
Supernus Pharmaceuticals USD 144.71M 28.86M Jun/2025
Teva Pharmaceutical Industries USD 2.16B 464M Jun/2025
Xeris Pharmaceuticals USD 59.28M 12.34M Jun/2025
Zoetis USD 1.44B 286M Jun/2025